New antibody therapy shows promise for Hard-to-Treat blood cancer
NCT ID NCT04773522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called JNJ-64407564 in 15 Japanese patients with multiple myeloma that had come back or stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal was to check safety and find the right dose for future studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Iwate Medical University Hospital
Shiwa-gun, 028-3695, Japan
-
Japanese Red Cross Medical Center
Shibuya City, 150-8935, Japan
-
Nagoya City University Hospital
Nagoya, 467 8602, Japan
-
National Cancer Center Hospital East
Kashiwa, 277 8577, Japan
-
National Hospital Organization Okayama Medical Center
Okayama, 701-1192, Japan
-
Shonan Kamakura General Hospital
Kamakura-shi, 247-8533, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact